Skip to main content
NCBI home page
Acta Pharmaceutica Sinica. B logoLink to Acta Pharmaceutica Sinica. B
. 2018 Jul 25;8(5):713–720. doi: 10.1016/j.apsb.2018.07.009

Ganglioside GD3 synthase (GD3S), a novel cancer drug target

Jinyi Liu a,c, Xiangjin Zheng b,c, Xiaocong Pang c, Li Li c, Jinhua Wang b,c,⁎, Cui Yang a,⁎, Guanhua Du b,c,⁎
PMCID: PMC6147802  PMID: 30245960

Abstract

Gangliosides are a class of important glycosphingolipids containing sialic acid that are widely distributed on the outer surface of cells and are abundantly distributed in brain tissue. Disialoganglioside with three glycosyl groups (GD3) and disialoganglioside with two glycosyl groups (GD2) are markedly increased in pathological conditions such as cancers and neurodegenerative diseases. GD3 and GD2 were found to play important roles in cancers by mediating cell proliferation, migration, invasion, adhesion, angiogenesis and in preventing immunosuppression of tumors. GD3 synthase (GD3S) is the regulatory enzyme of GD3 and GD2 synthesis, and is important in tumorigenesis and the development of cancers. The study of GD3S as a drug target may be of great significance for the discovery of new drugs for cancer treatment. This review will describe the gangliosides and their roles in physiological and pathological conditions; the roles of GD3 and GD2 in cancers; the expression, functions and mechanisms of GD3S, and its potential as a drug target in cancers.

KEY WORDS: Ganglioside, GD3, GD2, GD3S, Drug target, Cancer treatment

Graphical abstract

Gangliosides GD3 and GD2 are involved and further play important roles in many cancers. GD3 synthase (GD3S) is the only enzyme that regulates the biosynthesis of GD3 and GD2. The potential of GD3S to serve as a novel drug target in cancer is focused in this review.

fx1

Open in a new tab

1. Introduction

Cancer has become a major public health problem in China and the world1, 2. The incidence and mortality rates of cancer in China are still increasing2. Cancer is a multistep process which includes many processes, such as initiation, development, migration and metastasis3. Most patients with breast, lung, colon and ovarian cancer have been found to have metastatic colonies. Approximately 90% of patients with cancer died from cancer metastasis4. Conventional therapeutics are not effective for treatment of these cancers. Therefore, it is important to find novel drug targets for cancer treatment.

Gangliosides are present in many cells, especially in the nervous system5. Recent studies have shown that gangliosides GD3 and GD2 are involved and further play important roles in many cancers6, 7, 8. GD3 synthase (GD3S) is the only enzyme that regulates the biosynthesis of GD3 and GD2 and therefore exerts a significant effect on cancers. In this review, we present the classification of gangliosides, the physiological and pathological significance of gangliosides in humans, the roles of GD3 and GD2 in cancers, and the potential of GD3S to serve as a novel drug target in cancer.

2. Gangliosides

2.1. Definition and discovery of gangliosides

N-Acetylneuraminic acid, also known as sialic acid, is a carbohydrate released from brain glycolipids9. In general, glycolipid containing sialic acid is called ganglioside, also known as glycosphingolipid with sialic acid. Gangliosides are a subfamily of glycosphingolipids that contain one or more sialic acid residues, consisting of a hydrophilic sialic acid-containing oligosaccharide chain and a hydrophobic neuraminide. In 1935, Krok.ke first found that gangliosides accumulated in the brains of children with Tay-Sachs disease10. Gangliosides were later found to be widely distributed in the cell membranes of animal tissues, especially in the central nervous system and in melanomas5, 11.

2.2. Classification and nomenclature of gangliosides

Gangliosides can be divided into monosialogangliosides (GM), disialogangliosides (GD), trisialogangliosides (GT) and tetrasialoganglioside (GQ) according to the number of sialic acid residues per molecule. Gangliosides are usually named by the Svennerholm nomenclature12. The capital letter "G" represents the ganglioside and the next letter "M, D, T, Q, P, H or S" represents the number of 1–7 sialic acids, respectively; the following number represents different glycosyl groups in gangliosides (Fig. 1). More than 70 kinds of gangliosides have been isolated and identified.

Figure 1.

Figure 1

Open in a new tab

Classification of gangliosides. Gangliosides can be divided into monosialogangliosides (GM), disialogangliosides (GD), trisialogangliosides (GT) and tetrasialoganglioside (GQ) according to the number of sialic acid residues per molecule.

2.3. The physiological and pathological significance of gangliosides

Gangliosides are a family of acidic membrane glycolipids which exert important effects on cell development, differentiation and oncogenic transformation13. Gangliosides are sialic acid-containing glycolipids which are found on plasma membranes of nearly all vertebrate cells. GD3 plays essential roles in the development of normal brain and its levels are decreased in adults. In contrast, GD3 is upregulated in neuroectodermal and epithelial cancers14.

2.3.1. Roles of gangliosides in the central nervous system

Under normal physiological conditions, gangliosides are highly expressed in the central nervous system and promote the development of the nervous system5. Gangliosides are important for development of brain at early stages. They can promote the growth of neurons and axons, participate in the regulation of synapse plasticity, and are involved in the differentiation of neural cells. They are able to protect the function of nerves and promote regeneration of nerve by affecting certain cytokines as well15. Meanwhile, Gangliosides are also of great importance under pathological conditions. In Parkinson׳s disease, inhibition of ganglioside expression can reduce apoptosis of cells and protect nerves16. More than that, Gangliosides can also be targets for new drugs that inhibit β-amyloid aggregation to relieve Alzheimer׳s disease17.

2.3.2. Role of Gangliosides in cancers

In recent years, numerous studies showed that gangliosides are of significance in the occurrence and development of cancers. It was reported that the abnormal increase of gangliosides in serum is closely related to cancers18, 19. So detection of ganglioside in serum could be used to predict prognosis and recurrence of patients with cancers20, 21.

Gangliosides exert many functions by different mechanisms in cancers. Gangliosides like GD3 and GD2 are found to be closely related to immunity. Ganglioside antigens on the surface of cancer cells, or shedding from the cells, act as immunosuppressors, as typically observed for the suppression of cytotoxic T cells and dendritic cells22. Gangliosides promote tumor-associated angiogenesis22, 23 and strongly regulate cell adhesion/motility and thus initiate tumor metastasis22. Ganglioside antigens are directly connected with transducer molecules in microdomains to initiate adhesion. Ganglioside antigens and their catabolites are modulators of signal transduction by interacting with tyrosine kinases associated with growth factor receptors or other protein kinases22. Given the potential importance of these sialylated gangliosides and their modulating biological behavior in vivo, further studies on gangliosides are warranted.

3. Roles of GD3 and GD2 in cancers

Cancer is caused by both internal and environmental factors. Tumorigenesis is a multistep process including initiation, promotion and progression. The pathology of tumorigenesis is characterized by the accumulation of a multitude of alterations including genetic, cytogenetic, and epigenetic changes3, 24. Invasion and metastasis are the important hallmarks of cancers, which are also the biggest bottleneck in the treatment of cancers25. Cancer stem cells, which are closely associated with initiation, development, invasion and metastasis of cancers, have the ability of self-renewal and differentiation26. GD3 and GD2 are two very important gangliosides which exert many functions in tumorigenesis, development and metastasis. GD3 is the discovered earliest cancer-associated ganglioside that promotes adhesion and invasion of cancers. GD2 is used as a biomarker in a variety of cancer stem cells. GD3 and GD2 are highly expressed in a various malignant cancers and have become potential targets for next-generation cancer therapy.

3.1. The roles of GD3 in cancers

GD3 is a minor ganglioside in most normal tissues but plays a crucial role in the development of the brain. The expression of GD3 is significantly reduced in adults. However, expression of GD3 is increased in pathological conditions, such as cancers and neurodegenerative disorders27.

GD3 mediates many functions in cancers by different mechanisms (Fig. 2)7, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37. The expression of GD3 is up-regulated in neoplastic cells and it mediates the invasion and survival of cancers38. Intriguingly, GD3 can also regulate additional biological functions, such as cell proliferation and differentiation by stimulating expression of vascular endotheilial growth factor (VEGF)27. Neuroectodermic cancers can mostly be characterized by the presence of cancer-associated glycosphingolipid antigens, such as gangliosides22. GD3 is overexpressed in lymphangioleiomyomatosis (LAM)39. GD3 was also increased in plasma of children with T-cell acute lymphoblastic leukemia40. In particular, GD3 is highly expressed in melanomas and small cell lung cancer cells, and its abnormal expression promoted the growth and invasion of the cancer cells41. GD3 was isolated from the polar lipid fraction of ovarian cancer-associated ascites and functions as an inhibitory factor that prevents innate immune activation of natural killer T (NKT) cells. Purified GD3 displayed a high affinity for both human and mouse CD1d, which is involved in the presentation of lipid antigens to T cells. GD3 bound to the antigenic-binding site of CD1d and did not require additional processing for its inhibitory effect on NKT cells. Importantly, in vivo administration of GD3 inhibited α-galactosylceramide (α-GalCer)-induced NKT cell activation in a dose-dependent manner7. Significant increases of gangliosides (GM3 and GD3) profile in human cerebrospinal fluid (CSF) were correlated with blood–brain barrier dysfunction including CSF hemorrhages and compressive syndrome, and some malignant processes (metastatic brain melanoma) as well42. GD3 was found to be involved in formation of autophagosomes by interacting with core-initiator proteins of autophagy, such as autophagy and beclin 1 regulator 1 (AMBRA1) and WD repeat domain phosphoinositide-interacting protein 1 (WIPI1)28. GD3 was found to maintain the self-renewal capability of neural stem cells (NSCs) by interaction with EGFR, which sustains the expression of EGFR and its downstream signaling29. Physical association between GD3 and neogenin was confirmed by immunoblotting of immunoprecipitates with anti-neogenin antibody from GD3+ cell lysates. The intra-cytoplasmic domain of neogenin (Ne-ICD) was found in GD3+ cells at higher levels than in GD3– cells when cells were treated with a proteasome inhibitor. Exogenous GD3 also induced Ne-ICD expression in GD3– cells. Overexpression of Ne-ICD in GD3– cells resulted in increased growth and invasion of the cells, suggesting that Ne-ICD plays a role as a transcriptional factor to drive malignant properties of melanomas after cleavage with γ-secretase30. Knockdown of GD3 synthase resulted in the alleviation of tumor phenotypes and reduced activation levels of Src family kinase Yes whereas overexpression of GD3 enhanced the malignant properties of human melanoma cells by activating Yes31. Ganglioside GD3 enhances signals of adhesion and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched microdomains32. Apoptotic T cell levels from renal cell carcinoma (RCC) patients were higher than those from normal donors. GD3 plays a critical role in immune dysfunction observed in RCC patient T cells43. GD3 regulates the apoptosis of activated but not resting T cells44. The study from Ohkawa et al.45 showed that integrin-mediated signaling is essential in the effects of GD3 on the malignant properties of melanomas. Co-localization of GD3 and integrin at the focal adhesion supported these results. Overexpression of GD3 enhanced the association of focal adhesion kinase (FAK) with p130Cas after treatment of fetal calf serum. FAK as well as p130Cas and paxillin are crucial molecules undergoing stronger tyrosine phosphorylation in GD3-expressing melanoma cells33. GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells34. GD3 expression in target cells can mediate the cytotoxicity of NK cells via siglec-7-dependent and -independent mechanisms35. Monoclonal anti-GD3 antibodies were found to selectively inhibit the proliferation of human malignant glioma cells in vitro46. Expression of neural cell adhesion molecules (NCAM) was reduced while GD3 expression was increased during the migratory phase of brain tumor invasion. Both NCAM and GD3 promoted motile behavior of cells in neoplastic glia45. There is a correlation between advanced malignant melanoma and expression of GD3 antigen on patients׳ peripheral T-lymphocytes47. GD3 was highly expressed in hypervascularised areas of high grade gliomas, which support the involvement of the ganglioside in brain cancer angiogenesis48. GD3 was also found to protect human melanoma cells from ionizing radiation-induced clonogenic cell death49. A study from Koochekpour et al.37 showed that both TGF-βs and gangliosides may act as indirect angiogenic factors by stimulating secretion of VEGF. GD3 was found to be associated with immunity. GD3 was identified as a suppressor of the innate immune response in ovarian cancer7, and VEGF can potentiate immunosuppression mediated by GD350. GD3 is drug target of cancer treatment and antibody to GD3, ecromeximab (KW2871), was tested in a phase II study in clinical trials (Clinical trial number: NCT00679289)51.

Figure 2.

Figure 2

Open in a new tab

The mechanisms of GD3 function in cancer. GD3 plays important roles in different cancers by different pathways.

3.2. The roles of GD2 in cancers

3.2.1. Expression of GD2 in the tumor

There is low GD2 expression in most normal tissues whereas high GD2 expression in many malignant cancers. In particular, GD2 is highly expressed in melanomas and small cell lung cancer cells, and its expression promotes growth and invasion of cells41. GD2 is also highly prevalent in a cohort of breast cancer (BC) patients clustering on very aggressive breast cancer subtypes, such as triple-negative and metaplastic variants52. What׳s more, GD2 is highly expressed in sarcomas of children, adolescents and young adults53 and the majority of human osteosarcoma cell lines derived from oral cavity regions54. GD2 expression is maintained upon recurrence in patients with osteosarcoma55. Recently, GD2 can be used as a biomarker for identifying human NSCs56. Terzic et al.57 found that the expression of GD2 was detected in 96% of 152 neuroblastoma patients, and that its expression level varied from sample to sample. The expression level of GD2 in cancer cells can be used as a prognostic biomarker in neuroblastoma patients.

3.2.2. Biomarker of cancer stem cell

Interaction of GD2 with growth factor receptors maintains breast cancer stem cell phenotype58. GD2 may serve as a marker for identification and purification of murine bone marrow mesenchymal stem cells (mBM-MSCs)59. Meanwhile, Martinez et al.60 confirmed that cells selected by GD2 are a subpopulation of MSCs with features of primitive precursor cells. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2, which is a novel surface marker for the identification of MSCs60. It was reported that GD2 identified a small fraction of cells in human breast cancer cell lines and patient samples that were capable of forming mammospheres and initiating tumors with as few as 10 GD2+ cells. In addition, the majority of GD2+ cells are also CD44hiCD24lo, the previously established cancer stem cell (CSC)-associated cell surface phenotype. Further study revealed that GD3S was highly expressed in GD2+ as well as in CD44hiCD24lo cells, and that interference with GD3S expression, either by shRNA or using a pharmacological inhibitor, significantly reduced the CSC population and CSC-associated properties61.

3.2.3. Mechanisms of GD2 in cancer

GD2 is involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. GD2 enhanced platelet adhesion to extracellular matrix collagen by upregulating integrin α2β1-mediated tyrosine phosphorylation of p125FAK, thereby providing insight into how this interaction may be involved in neuroblastoma metastasis62. The study from Ito et al.63 showed that GD2 could specifically bind siglec7 to promote the development of renal cell carcinoma.

3.2.4. Drug target of cancer immunotherapy

GD2 was found to be associated with immunity and anti-GD2 antibody was used as immunotherapy for neuroblastoma64. In 2015, dinutuximab (an anti-GD2 mAb) was approved by the US Food and Drug Administration (FDA) and is currently used in a combination immunotherapeutic regimen for the treatment of children with high-risk neuroblastoma65. However, dinutuximab can cause many adverse effects including neuropathic pain, hypotension, and fever, which limit its use66, 67. GD2 was also used as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma68.

4. GD3S, a novel drug target in cancer

4.1. Structure of GD3S

The gene coding for human GD3S is located in the p12 region of chromosome 12. In 1994, Sasaki et al.69 and Nara et al.70 isolated and cloned a GD3S cDNA, respectively. Transcripts of the GD3S gene encode a 356 amino acid protein that is mainly located in the Golgi apparatus. The first 29 amino acids are located in the cytoplasm. Amino acids 30–48 are in helical structure and cross the membrane of Golgi. The remainder of the protein is in the Golgi chamber, which is the catalytic part of GD3S.

GD3S is an α-N-acetylneuraminide α-2,8-sialyltransferase. GD3S transfers the sialic acid residues from donor CMP-N-acetylneuraminate to the α-sialic acid residue of the receptor GM3 and thus generates GD3 and CMP. GD3S is one of six members of the ST8Sia subfamily of sialyltransferases (ST8Sia I-VI), often referred as ST8Sia I. Sequence analysis reveals that the ST8sia enzyme family can be divided into two groups: one is oligo/polysialyltransferase including ST8Sias II, III, and IV; the other is a single sialyltransferase whose members are ST8Sias I, V and VI71. The crystal structure of the ST8Sia III catalytic domain was resolved by Volkers et al.72 in 2015, which revealed the binding mechanism of its substrate and catalytic reaction mechanism. According to the similarities among ST8Sia subfamilies, the catalytic domain of GD3S can be obtained by comparing the primary amino acid sequences of ST8Sia I and ST8Sia III. It is also possible to speculate that some asparagine residues of GD3S may be glycosylated, such as N71, N119, N214 and N245. However, the precise three-dimensional structure of GD3S, the location and type of post-translational modification, the substrate recognition mechanism and the catalytic reaction mechanism still need further study.

4.2. GD3S expression in cancers

GD3 and GD2 are overexpressed in a variety of malignant cancers. GD3S is the only enzyme which regulates biosynthesis of GD3 and GD2 (Fig. 3). GD3S is highly expressed in many cancers and exerts various functions in initiation and development of cancers.

Figure 3.

Figure 3

Open in a new tab

Pathways in biosynthesis of GD3 and GD2. GD3S is the only enzyme which regulates biosynthesis of GD3 and GD2. GM3 is converted into GD3 by the catalysis of GD3S and GD3 is converted into GD2 by the catalysis of GD2S.

4.2.1. Breast cancer

CD44+ CD24– is a biomarker of breast cancer stem cells. It was reported that GD3S was highly expressed in GD2+ breast cancer stem cells, which were also CD44+ CD24– breast cancer cells. Decreasing the expression of GD3S can inhibit proliferation and self-renewal of cancer stem cells. Inhibition of GD3S also reduced growth of tumor in vivo61. A study showed that overexpression of GD3S could induce the accumulation of GD2 and GD3 in the membrane of the breast cancer cell line MDA-MB-231 and promote proliferation of cells by activating c-Met and the downstream targets MEK/ERK and the PI3K/AKT pathway73. GD3S promoted metastasis of breast cancer by regulating epithelial mesenchymal transition (EMT). A study also showed that overexpression of GD3S increased the invasion and metastasis of breast cancer, and that metastasis of cancer was blocked by inhibiting the expression of GD3S74.

4.2.2. Melanoma

GD3S is a specific antigen in melanoma. GD3S is overexpressed in many melanoma cell lines, such as M14 and SK-MEL-2 cells, and promote the development of melanoma75, 76. Hamamura et al.34 found that GD3S increased proliferation and invasion of cells by activating p130Cas, paxillin and the AKT pathway in melanoma. Overexpression of GD3S improved the adhesion of cancer cells to many kinds of extracellular matrixes and further promoted development of melanoma32. GD3S was overexpressed and promoted proliferation and metastasis in melanoma cell line SK-MEL-2 and that NF-κB regulated transcription of GD3S and growth of cancers was inhibited when biosynthesis of GD3S was blocked77.

4.2.3. Glioma

Glioma is a very malignant cancer with high recurrence. GD3S was also found to be highly expressed in patients with glioma. Many studies showed that CD133 could be used as a biomarker of glioma stem cells78, 79, 80. However, CD133 was expressed not only in glioma stem cells, but also in many other cancers like colon cancer, retinoblastoma and leukemias81. Yeh et al.82 studied the role of gangliosides in glioma stem cells and found that GD3 and GD2 were highly expressed in glioma stem cells. In consideration of the regulation of GD3S in the expression of GD3 and GD2, they further determined that combination of GD3S and CD133 could be used as a biomarker of glioma stem cells. GD3S promoted formation of spheres and the growth of glioma stem cells. Cancer was inhibited when expression of GD3S was interrupted, which suggested that GD3S played an essential role in glioma stem cells82.

4.2.4. Other tumors

Ko et al.83 found that GD3S was highly expressed in lung cancer, and that inhibition of GD3S by siRNA reduced expression of GD2 and inhibited proliferation, migration and invasion of cells. Proliferation of PC12 cells, a rat pheochromocy, was increased and phosphorylation of TrkA and ERK1/2 activation was detected when cells were transfected with a GD3S expression plasmid, suggesting that cell proliferation was mediated by Ras/MEK/ERK84. Overexpression of GD3S sensitized hepatocarcinoma cells to hypoxia and reduced tumor growth by suppressing the cSrc/NF-κB survival pathway85. GD3S was overexpressed in melanomas and up-regulated in activated T lymphocytes86. Cell migration, tumor growth and experimental metastasis of rat F-11 cells were reduced when expression of GD3S was suppressed87.

4.3. Regulation of GD3S expression and potential as a drug target

Bobowski et al.88 identified the corresponding core promoter of GD3S in Hs578T breast cancer cells and showed that estradiol reduced mRNA expression of ST8SIA1 in estrogen receptor alpha (ERα) positive MCF-7 cells. The activity of the core promoter sequence of ST8SIA1 is also repressed by estradiol. Although there were two putative estrogen response elements (ERE) in the core promoter of ST8SIA1, they were not found to be involved in the promoter activity. However, NF-κB was found to be involved in ST8SIA1 transcriptional activation. Further study showed that estradiol prevented NF-κB to bind to the ST8SIA1 core promoter in ERα-expressing breast cancer cells by inhibiting the nuclear localization of p56 and p5088. Triptolide (TPL) was found to down-regulate expression of GD3S through NF-κB activation in human melanoma cells89. On the contrary, valproic acid induces transcriptional activation of human GD3S in SK-N-BE(2)-C human neuroblastoma cells90. Kang et al.77 showed that the core promoter from –1146 to –646 was indispensable for expression of human GD3S, and that the core promoter lacked apparent TATA and CAAT boxes but contained putative binding sites for transcription factors c-Ets-1 (Protein C-Ets-1), CREB, AP-1 and NF-κB in human melanoma SK-MEL-2 cells77. In addition, another study also indicated that NF-κB played an essential role in the transcriptional activity of human GD3S gene in Fas-induced Jurkat T cells. Furthermore, the translocation of NF-κB-binding protein to the nucleus by Fas activation was also crucial for the increased expression of the GD3S gene in Fas-activated Jurkat T cells91.

4.4. Study on an inhibitor of GD3S

Many studies showed that GD3S exerted significant functions in development of cancers. GD3S was also found to be related to immunity which was associated with initation and development of cancers. The expression of GD3S in melanoma was associated with up-regulation in activated T lymphocytes86. A study of small interfering RNAs for GD3S showed that GD3S could be used as a therapeutic target of lung cancers83.

Inhibition of GD3S can block biosynthesis of GD3 and GD2, thus reduces proliferation, migration and invasion of cancer cells. Therefore, GD3S may be used as potential drug target for many cancers. Up to now, there are few studies on GD3S inhibitors. The only reported GD3S inhibitor is triptolide. Triptolide, an epoxy diterpene lactone, is one of the main active components extracted from the roots, leaves, flowers and fruits of the Tripterygium92. It is a natural product with a variety of biological activities. Studies have shown that triptolide has anti-oxidation, and anti-rheumatism effects93, 94. It has also been reported that triptolide has a good therapeutic effect in pancreatic cancer, prostate cancer and bladder cancer95, 96, 97. Kwon et al.89 found that triptolide inhibited cell proliferation by downregulating the expression of GD3S in human melanoma SK-MEL-2 cells. Sarkar et al.74 also found that triptolide inhibited the development of tumors by inhibiting the function of GD3S in breast cancer.

5. Summary and perspective

In recent years, great progress has been made in the study of gangliosides. As the key enzyme in the biosynthesis of GD3 and GD2, GD3S importantly functions in the development of the nervous system, the maintenance and repair of neural stem cells, the repair of nerves, and the growth, proliferation, infiltration and metastasis of cancers. The important roles of GD3S in cancers suggest that inhibitors of GD3S have good development and application prospects. GD3S inhibitors will be a focus of research on cancer drugs in the future. GD3S is highly expressed in a variety of cancers, but the regulation, especially the epigenetic regulation of its expression is still not clear. Bioinformatics analysis shows that methylation level of the GD3S promoter is very low. In addition, the mechanism of GD3S in cancers is still to be fully elucidated. Both GD3 and GD2 are found to be closely related to immunity. Currently there are few studies on GD3S and immune regulation. Therefore, the role of GD3S in cancer immunity needs further study in future. These studies on GD3S will be of great significance to understand the regulation of GD3S expression in cancers, its mechanism of action and the discovery of inhibitors.

Acknowledgements

This work was supported by National Natural Science Foundation of China (81573454) and supported by Beijing Natural Science Foundation (7172142). This work was also supported by CAMS Innovation Fund for Medical Sciences (2016-I2M-3–007).

Footnotes

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.

Contributor Information

Jinhua Wang, Email: wjh@imm.ac.cn.

Cui Yang, Email: yangynni@163.com.

Guanhua Du, Email: dugh@imm.ac.cn.

References

  • 1.Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi: 10.3322/caac.21387. [DOI] [PubMed] [Google Scholar]
  • 2.Chen W., Zheng R., Baade P.D., Zhang S., Zeng H., Bray F. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi: 10.3322/caac.21338. [DOI] [PubMed] [Google Scholar]
  • 3.Bishop J.M. Molecular themes in oncogenesis. Cell. 1991;64:235–248. doi: 10.1016/0092-8674(91)90636-d. [DOI] [PubMed] [Google Scholar]
  • 4.Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5:402–418. doi: 10.1016/j.apsb.2015.07.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Schnaar R.L., Gerardy-Schahn R., Hildebrandt H. Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Physiol Rev. 2014;94:461–518. doi: 10.1152/physrev.00033.2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Groux-Degroote S., Guerardel Y., Julien S., Delannoy P. Gangliosides in breast cancer: new perspectives. Biochemistry (Mosc) 2015;80:808–819. doi: 10.1134/S0006297915070020. [DOI] [PubMed] [Google Scholar]
  • 7.Webb T.J., Li X., Giuntoli R.L. 2nd, Lopez P.H., Heuser C., Schnaar R.L. Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res. 2012;72:3744–3752. doi: 10.1158/0008-5472.CAN-11-2695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Doronin I.I., Vishnyakova P.A., Kholodenko I.V., Ponomarev E.D., Ryazantsev D.Y., Molotkovskaya I.M. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer. 2014;14:295. doi: 10.1186/1471-2407-14-295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Varki A., Schnaar R.L., Schauer R. Sialic acids and other nonulosonic acids. In: Varki A., Cummings R.D., Esko J.D., Stanley P., Hart G.M., Aebi M., editors. Essentials of glycobiology. Cold Spring Harbor Laboratory Press; NY: 2015. pp. 179–195. [Google Scholar]
  • 10.Ning N., Chen N.H. Biological activity of gangliosides. Prog Physiol Sci. 2009;40:24–30. [PubMed] [Google Scholar]
  • 11.Furukawa K., Kambe M., Miyata M., Ohkawa Y., Tajima O., Furukawa K. Ganglioside GD3 induces convergence and synergism of adhesion and hepatocyte growth factor/Met signals in melanomas. Cancer Sci. 2014;105:52–63. doi: 10.1111/cas.12310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Svennerholm L. Chromatographic separation of human brain gangliosides. J Neurochem. 1963;10:613–623. doi: 10.1111/j.1471-4159.1963.tb08933.x. [DOI] [PubMed] [Google Scholar]
  • 13.Maidment S.L., Merzak A., Koochekpour S., Rooprai H.K., Rucklidge G.J., Pilkington G.J. The effect of exogenous gangliosides on matrix metalloproteinase secretion by human glioma cells in vitro. Eur J Cancer. 1996;32a:868–871. doi: 10.1016/0959-8049(95)00659-1. [DOI] [PubMed] [Google Scholar]
  • 14.Torres Demichelis V., Vilcaes A.A., Iglesias-Bartolome R., Ruggiero F.M., Daniotti J.L. Targeted delivery of immunotoxin by antibody to ganglioside GD3: a novel drug delivery route for tumor cells. PLoS One. 2013;8:e55304. doi: 10.1371/journal.pone.0055304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Roberti R., Binaglia L., Francescangeli E., Goracci G., Porcellati G. Enzymic synthesis of 1-alkyl-2-acyl-sn-glycero-3-phosphorylethanolamine through ethanolaminephosphotransferase activity in the neuronal and glial cells of rabbit in vitro. Lipids. 1975;10:121–127. doi: 10.1007/BF02534148. [DOI] [PubMed] [Google Scholar]
  • 16.Akkhawattanangkul Y., Maiti P., Xue Y., Aryal D., Wetsel W.C., Hamilton D. Targeted deletion of GD3 synthase protects against MPTP-induced neurodegeneration. Genes Brain Behav. 2017;16:522–536. doi: 10.1111/gbb.12377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Bernardo A., Harrison F.E., McCord M., Zhao J., Bruchey A., Davies S.S. Elimination of GD3 synthase improves memory and reduces amyloid-β plaque load in transgenic mice. Neurobiol Aging. 2009;30:1777–1791. doi: 10.1016/j.neurobiolaging.2007.12.022. [DOI] [PubMed] [Google Scholar]
  • 18.Diatlovitskaia E.V., Somova O.G., Novikov A.M., Sorokin E.N., Bassalyk L.S. Ganglioside GD3 in the serum of tumor patients. Biokhimiia. 1985;50:1933–1935. [PubMed] [Google Scholar]
  • 19.Somova O.G., Tekieva E.A., Diatlovitskaia E.V., Bassalyk L.S., Bergel׳son L.D. Ganglioside (GD3) in serum of cancer patients. Vopr Med Khim. 1991;37:21–23. [PubMed] [Google Scholar]
  • 20.Nakamura O., Iwamori M., Matsutani M., Takakura K. Ganglioside GD3 shedding by human gliomas. Acta Neurochir (Wien) 1991;109:34–36. doi: 10.1007/BF01405694. [DOI] [PubMed] [Google Scholar]
  • 21.Fumic K., Vladovic-Relja T., Karada J., Kracun I., Stavljenic A., Kubat M. Gangliosides in the serum in lung carcinoma. Lijec Vjesn. 1990;112:7–12. [PubMed] [Google Scholar]
  • 22.Birkle S., Zeng G., Gao L., Yu R.K., Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie. 2003;85:455–463. doi: 10.1016/s0300-9084(03)00006-3. [DOI] [PubMed] [Google Scholar]
  • 23.Gullino P.M. Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. Acta Oncol. 1995;34:439–441. doi: 10.3109/02841869509094005. [DOI] [PubMed] [Google Scholar]
  • 24.Heard E., Martienssen R.A. Transgenerational epigenetic inheritance: myths and mechanisms. Cell. 2014;157:95–109. doi: 10.1016/j.cell.2014.02.045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science. 2011;331:1559–1564. doi: 10.1126/science.1203543. [DOI] [PubMed] [Google Scholar]
  • 26.Magee J.A., Piskounova E., Morrison S.J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012;21:283–296. doi: 10.1016/j.ccr.2012.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Malisan F., Testi R. GD3 ganglioside and apoptosis. Biochim Biophys Acta. 2002;1585:179–187. doi: 10.1016/s1388-1981(02)00339-6. [DOI] [PubMed] [Google Scholar]
  • 28.Garofalo T., Matarrese P., Manganelli V., Marconi M., Tinari A., Gambardella L. Evidence for the involvement of lipid rafts localized at the ER-mitochondria associated membranes in autophagosome formation. Autophagy. 2016;12:917–935. doi: 10.1080/15548627.2016.1160971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wang J., Yu R.K. Interaction of ganglioside GD3 with an EGF receptor sustains the self-renewal ability of mouse neural stem cells in vitro. Proc Natl Acad Sci U S A. 2013;110:19137–19142. doi: 10.1073/pnas.1307224110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kaneko K., Ohkawa Y., Hashimoto N., Ohmi Y., Kotani N., Honke K. Neogenin, defined as a GD3-associated molecule by enzyme-mediated activation of radical sources, confers malignant properties via intracytoplasmic domain in melanoma cells. J Biol Chem. 2016;291:16630–16643. doi: 10.1074/jbc.M115.708834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Hamamura K., Tsuji M., Hotta H., Ohkawa Y., Takahashi M., Shibuya H. Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3. J Biol Chem. 2011;286:18526–18537. doi: 10.1074/jbc.M110.164798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ohkawa Y., Miyazaki S., Hamamura K., Kambe M., Miyata M., Tajima O. Ganglioside GD3 enhances adhesion signals and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched microdomains. J Biol Chem. 2010;285:27213–27223. doi: 10.1074/jbc.M109.087791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Hamamura K., Tsuji M., Ohkawa Y., Nakashima H., Miyazaki S., Urano T. Focal adhesion kinase as well as p130Cas and paxillin is crucially involved in the enhanced malignant properties under expression of ganglioside GD3 in melanoma cells. Biochim Biophys Acta. 2008;1780:513–519. doi: 10.1016/j.bbagen.2007.11.002. [DOI] [PubMed] [Google Scholar]
  • 34.Hamamura K., Furukawa K., Hayashi T., Hattori T., Nakano J., Nakashima H. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc Natl Acad Sci U S A. 2005;102:11041–11046. doi: 10.1073/pnas.0503658102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Nicoll G., Avril T., Lock K., Furukawa K., Bovin N., Crocker P.R. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur J Immunol. 2003;33:1642–1648. doi: 10.1002/eji.200323693. [DOI] [PubMed] [Google Scholar]
  • 36.Gratsa A., Rooprai H.K., Rogers J.P., Martin K.K., Pilkington G.J. Correlation of expression of NCAM and GD3 ganglioside to motile behaviour in neoplastic glia. Anticancer Res. 1997;17:4111–4117. [PubMed] [Google Scholar]
  • 37.Koochekpour S., Merzak A., Pilkington G.J. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-β isoforms in human glioma cells in vitro. Cancer Lett. 1996;102:209–215. doi: 10.1016/0304-3835(96)04161-4. [DOI] [PubMed] [Google Scholar]
  • 38.Birks S.M., Danquah J.O., King L., Vlasak R., Gorecki D.C., Pilkington G.J. Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma. Neuro Oncol. 2011;13:950–960. doi: 10.1093/neuonc/nor108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Gilbert E.R., Eby J.M., Hammer A.M., Klarquist J., Christensen D.G., Barfuss A.J. Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis. Am J Pathol. 2013;183:226–234. doi: 10.1016/j.ajpath.2013.04.002. [DOI] [PubMed] [Google Scholar]
  • 40.Merritt W.D., Der-Minassian V., Reaman G.H. Increased GD3 ganglioside in plasma of children with T-cell acute lymphoblastic leukemia. Leukemia. 1994;8:816–822. [PubMed] [Google Scholar]
  • 41.Furukawa K., Hamamura K., Ohkawa Y., Ohmi Y., Furukawa K. Disialyl gangliosides enhance tumor phenotypes with differential modalities. Glycoconj J. 2012;29:579–584. doi: 10.1007/s10719-012-9423-0. [DOI] [PubMed] [Google Scholar]
  • 42.Trbojevic-Cepe M., Kracun I., Jusic A., Pavlicek I. Gangliosides of human cerebrospinal fluid in various neurologic diseases. J Neurol Sci. 1991;105:192–199. doi: 10.1016/0022-510x(91)90144-v. [DOI] [PubMed] [Google Scholar]
  • 43.Biswas S., Biswas K., Richmond A., Ko J., Ghosh S., Simmons M. Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol. 2009;183:5050–5058. doi: 10.4049/jimmunol.0900259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Sa G., Das T., Moon C., Hilston C.M., Rayman P.A., Rini B.I. GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res. 2009;69:3095–3104. doi: 10.1158/0008-5472.CAN-08-3776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Ohkawa Y., Miyazaki S., Miyata M., Hamamura K., Furukawa K., Furukawa K. Essential roles of integrin-mediated signaling for the enhancement of malignant properties of melanomas based on the expression of GD3. Biochem Biophys Res Commun. 2008;373:14–19. doi: 10.1016/j.bbrc.2008.05.149. [DOI] [PubMed] [Google Scholar]
  • 46.Hedberg K.M., Dellheden B., Wikstrand C.J., Fredman P. Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro. Glycoconj J. 2000;17:717–726. doi: 10.1023/a:1011026823362. [DOI] [PubMed] [Google Scholar]
  • 47.Welte B., Handgretinger R., Rassner G., Fierlbeck G. Expression of GD3 disialoganglioside antigen on peripheral T-lymphocytes in patients with disseminated malignant melanoma. Exp Dermatol. 1997;6:64–69. doi: 10.1111/j.1600-0625.1997.tb00148.x. [DOI] [PubMed] [Google Scholar]
  • 48.Koochekpour S., Pilkington G.J. Vascular and perivascular GD3 expression in human glioma. Cancer Lett. 1996;104:97–102. doi: 10.1016/0304-3835(96)04231-0. [DOI] [PubMed] [Google Scholar]
  • 49.Thomas C.P., Buronfosse A., Combaret V., Pedron S., Fertil B., Portoukalian J. Gangliosides protect human melanoma cells from ionizing radiation-induced clonogenic cell death. Glycoconj J. 1996;13:377–384. doi: 10.1007/BF00731470. [DOI] [PubMed] [Google Scholar]
  • 50.Tiper I.V., Temkin S.M., Spiegel S., Goldblum S.E., Giuntoli R.L., II, Oelke M. VEGF potentiates GD3-mediated immunosuppression by human ovarian cancer cells. Clin Cancer Res. 2016;22:4249–4258. doi: 10.1158/1078-0432.CCR-15-2518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Tarhini A.A., Moschos S.J., Lin Y., Lin H.M., Sander C., Yin Y. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma. Melanoma Res. 2017;27:342–350. doi: 10.1097/CMR.0000000000000353. [DOI] [PubMed] [Google Scholar]
  • 52.Orsi G., Barbolini M., Ficarra G., Tazzioli G., Manni P., Petrachi T. GD2 expression in breast cancer. Oncotarget. 2017;8:31592–31600. doi: 10.18632/oncotarget.16363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Dobrenkov K., Ostrovnaya I., Gu J., Cheung I.Y., Cheung N.K. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer. 2016;63:1780–1785. doi: 10.1002/pbc.26097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Shibuya H., Hamamura K., Hotta H., Matsumoto Y., Nishida Y., Hattori H. Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci. 2012;103:1656–1664. doi: 10.1111/j.1349-7006.2012.02344.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Poon V.I., Roth M., Piperdi S., Geller D., Gill J., Rudzinski E.R. Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. Clin Sarcoma Res. 2015;5:4. doi: 10.1186/s13569-014-0020-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Yanagisawa M., Yoshimura S., Yu R.K. Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells. ASN Neuro. 2011;3:e00054. doi: 10.1042/AN20110006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Terzic T, Cordeau M, Herblot S, Teira P, Cournoyer S, Beaunoyer M, et al. Expression of disialoganglioside (GD2) in neuroblastic tumors: a prognostic value for patients treated with anti-D2 immunotherapy. Pediatr Dev Pathol 2017. Available from: 10.1177/1093526617723972 [DOI] [PubMed]
  • 58.Liang Y.J., Wang C.Y., Wang I.A., Chen Y.W., Li L.T., Lin C.Y. Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype. Oncotarget. 2017;8:47454–47473. doi: 10.18632/oncotarget.17665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Xu J., Fan W., Tu X.X., Zhang T., Hou Z.J., Guo T. Neural ganglioside GD2+ cells define a subpopulation of mesenchymal stem cells in adult murine bone marrow. Cell Physiol Biochem. 2013;32:889–898. doi: 10.1159/000354492. [DOI] [PubMed] [Google Scholar]
  • 60.Martinez C., Hofmann T.J., Marino R., Dominici M., Horwitz E.M. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood. 2007;109:4245–4248. doi: 10.1182/blood-2006-08-039347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Battula V.L., Shi Y., Evans K.W., Wang R.Y., Spaeth E.L., Jacamo R.O. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Investig. 2012;122:2066–2078. doi: 10.1172/JCI59735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Cheresh D.A., Pierschbacher M.D., Herzig M.A., Mujoo K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol. 1986;102:688–696. doi: 10.1083/jcb.102.3.688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Ito A., Handa K., Withers D.A., Satoh M., Hakomori S. Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression. FEBS Lett. 2001;504:82–86. doi: 10.1016/s0014-5793(01)02734-x. [DOI] [PubMed] [Google Scholar]
  • 64.Sait S., Modak S. Anti-GD2 immunotherapy for neuroblastoma. Expert Rev Anticancer Ther. 2017;17:889–904. doi: 10.1080/14737140.2017.1364995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Greenwood K., Foster J.H. Dinutuximab for the treatment of pediatric patients with neuroblastoma. Drugs Today (Barc) 2017;53:469–476. doi: 10.1358/dot.2017.53.9.2693023. [DOI] [PubMed] [Google Scholar]
  • 66.Fleurence J., Fougeray S., Bahri M., Cochonneau D., Clémenceau B., Paris F. Targeting O-acetyl-GD2 ganglioside for cancer immunotherapy. J Immunol Res. 2017;2017:5604891. doi: 10.1155/2017/5604891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Hoy S.M. Dinutuximab: a review in high-risk neuroblastoma. Target Oncol. 2016;11:247–253. doi: 10.1007/s11523-016-0420-2. [DOI] [PubMed] [Google Scholar]
  • 68.Roth M., Linkowski M., Tarim J., Piperdi S., Sowers R., Geller D. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer. 2014;120:548–554. doi: 10.1002/cncr.28461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Sasaki K., Kurata K., Kojima N., Kurosawa N., Ohta S., Hanai N. Expression cloning of a GM3-specific α-2,8-sialyltransferase (GD3 synthase) J Biol Chem. 1994;269:15950–15956. [PubMed] [Google Scholar]
  • 70.Nara K., Watanabe Y., Maruyama K., Kasahara K., Nagai Y., Sanai Y. Expression cloning of a CMP-NeuAc:neuac α 2-3Gal β 1-4Glc β 1-1'Cer α 2,8-sialyltransferase (GD3 synthase) from human melanoma cells. Proc Natl Acad Sci U S A. 1994;91:7952–7956. doi: 10.1073/pnas.91.17.7952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Huang R.B., Cheng D., Liao S.M., Lu B., Wang Q.Y., Xie N.Z. The intrinsic relationship between structure and function of the sialyltransferase ST8Sia family members. Curr Top Med Chem. 2017;17:2359–2369. doi: 10.2174/1568026617666170414150730. [DOI] [PubMed] [Google Scholar]
  • 72.Volkers G., Worrall L.J., Kwan D.H., Yu C.C., Baumann L., Lameignere E. Structure of human ST8SiaIII sialyltransferase provides insight into cell-surface polysialylation. Nat Struct Mol Biol. 2015;22:627–635. doi: 10.1038/nsmb.3060. [DOI] [PubMed] [Google Scholar]
  • 73.Cazet A., Lefebvre J., Adriaenssens E., Julien S., Bobowski M., Grigoriadis A. GD3 synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res. 2010;8:1526–1535. doi: 10.1158/1541-7786.MCR-10-0302. [DOI] [PubMed] [Google Scholar]
  • 74.Sarkar T.R., Battula V.L., Werden S.J., Vijay G.V., Ramirez-Peña E.Q., Taube J.H. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene. 2015;34:2958–2967. doi: 10.1038/onc.2014.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Dippold W.G., Lloyd K.O., Li L.T., Ikeda H., Oettgen H.F., Old L.J. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1980;77:6114–6118. doi: 10.1073/pnas.77.10.6114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Yamaguchi H., Furukawa K., Fortunato S.R., Livingston P.O., Lloyd K.O., Oettgen H.F. Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci U S A. 1987;84:2416–2420. doi: 10.1073/pnas.84.8.2416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Kang N.Y., Kim C.H., Kim K.S., Ko J.H., Lee J.H., Jeong Y.K. Expression of the human CMP-NeuAc:gm3 α 2,8-sialyltransferase (GD3 synthase) gene through the NF-κB activation in human melanoma SK-MEL-2 cells. Biochim Biophys Acta. 2007;1769:622–630. doi: 10.1016/j.bbaexp.2007.08.001. [DOI] [PubMed] [Google Scholar]
  • 78.Beier D., Hau P., Proescholdt M., Lohmeier A., Wischhusen J., Oefner P.J. CD133+ and CD133– glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67:4010–4015. doi: 10.1158/0008-5472.CAN-06-4180. [DOI] [PubMed] [Google Scholar]
  • 79.Brescia P., Ortensi B., Fornasari L., Levi D., Broggi G., Pelicci G. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells. 2013;31:857–869. doi: 10.1002/stem.1317. [DOI] [PubMed] [Google Scholar]
  • 80.Tamura K., Aoyagi M. CD133-positive stem cells. Response. J Neurosurg. 2014;120:1012. [PubMed] [Google Scholar]
  • 81.Meregalli M., Farini A., Belicchi M., Torrente Y. CD133+ cells isolated from various sources and their role in future clinical perspectives. Expert Opin Biol Ther. 2010;10:1521–1528. doi: 10.1517/14712598.2010.528386. [DOI] [PubMed] [Google Scholar]
  • 82.Yeh S.C., Wang P.Y., Lou Y.W., Khoo K.H., Hsiao M., Hsu T.L. Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity. Proc Natl Acad Sci U S A. 2016;113:5592–5597. doi: 10.1073/pnas.1604721113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Ko K., Furukawa K., Takahashi T., Urano T., Sanai Y., Nagino M. Fundamental study of small interfering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers. Oncogene. 2006;25:6924–6935. doi: 10.1038/sj.onc.1209683. [DOI] [PubMed] [Google Scholar]
  • 84.Fukumoto S., Mutoh T., Hasegawa T., Miyazaki H., Okada M., Goto G. GD3 synthase gene expression in PC12 cells results in the continuous activation of TrkA and ERK1/2 and enhanced proliferation. J Biol Chem. 2000;275:5832–5838. doi: 10.1074/jbc.275.8.5832. [DOI] [PubMed] [Google Scholar]
  • 85.Lluis J.M., Llacuna L., Von Montfort C., Bárcena C., Enrich C., Morales A. GD3 synthase overexpression sensitizes hepatocarcinoma cells to hypoxia and reduces tumor growth by suppressing the cSrc/NF-κB survival pathway. PLoS One. 2009;4:e8059. doi: 10.1371/journal.pone.0008059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Yamashiro S., Okada M., Haraguchi M., Furukawa K., Lloyd K.O., Shiku H. Expression of α2,8-sialyltransferase (GD3 synthase) gene in human cancer cell lines: high level expression in melanomas and up-regulation in activated T lymphocytes. Glycoconj J. 1995;12:894–900. doi: 10.1007/BF00731251. [DOI] [PubMed] [Google Scholar]
  • 87.Zeng G., Gao L., Yu R.K. Reduced cell migration, tumor growth and experimental metastasis of rat F-11 cells whose expression of GD3-synthase is suppressed. Int J Cancer. 2000;88:53–57. doi: 10.1002/1097-0215(20001001)88:1<53::aid-ijc8>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  • 88.Bobowski M., Vincent A., Steenackers A., Colomb F., Van Seuningen I., Julien S. Estradiol represses the GD3 synthase gene ST8SIA1 expression in human breast cancer cells by preventing NFκB binding to ST8SIA1 promoter. PLoS One. 2013;8:e62559. doi: 10.1371/journal.pone.0062559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Kwon H.Y., Kim S.J., Kim C.H., Son S.W., Kim K.S., Lee J.H. Triptolide downregulates human GD3 synthase (hST8Sia I) gene expression in SK-MEL-2 human melanoma cells. Exp Mol Med. 2010;42:849–855. doi: 10.3858/emm.2010.42.12.088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Kwon H.Y., Dae H.M., Song N.R., Kim K.S., Kim C.H., Lee Y.C. Valproic acid induces transcriptional activation of human GD3 synthase (hST8Sia I) in SK-N-BE(2)-C human neuroblastoma cells. Mol Cells. 2009;27:113–118. doi: 10.1007/s10059-009-0012-4. [DOI] [PubMed] [Google Scholar]
  • 91.Kang N.Y., Kang S.K., Lee Y.C., Choi H.J., Lee Y.S., Cho S.Y. Transcriptional regulation of the human GD3 synthase gene expression in Fas-induced Jurkat T cells: a critical role of transcription factor NF-κB in regulated expression. Glycobiology. 2006;16:375–389. doi: 10.1093/glycob/cwj087. [DOI] [PubMed] [Google Scholar]
  • 92.Cheng Q., Tong Y., Wang Z., Su P., Gao W., Huang L. Molecular cloning and functional identification of a cDNA encoding 4-hydroxy-3-methylbut-2-enyl diphosphate reductase from Tripterygium wilfordii. Acta Pharm Sin B. 2017;7:208–214. doi: 10.1016/j.apsb.2016.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Cui J., Chen X., Su J.C. Advanced progress of main pharmacology activities of triptolide. China J Chin Mater Med. 2017;42:2655–2658. doi: 10.19540/j.cnki.cjcmm.20170609.011. [DOI] [PubMed] [Google Scholar]
  • 94.Li X.J., Jiang Z.Z., Zhang L.Y. Triptolide: progress on research in pharmacodynamics and toxicology. J Ethnopharm. 2014;155:67–79. doi: 10.1016/j.jep.2014.06.006. [DOI] [PubMed] [Google Scholar]
  • 95.Han Y., Huang W., Liu J., Liu D., Cui Y., Huang R. Triptolide inhibits the AR signaling pathway to suppress the proliferation of enzalutamide resistant prostate cancer cells. Theranostics. 2017;7:1914–1927. doi: 10.7150/thno.17852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Yang L.L., Wang X.Y., Zheng L.Y., Fang S.J., Xu M., Zhao Z.W. The role of FOXO3a-Bim signaling in triptolide induced bladder cancer T24 cells apoptosis. Natl Med J China. 2017;97:1187–1190. doi: 10.3760/cma.j.issn.0376-2491.2017.15.016. [DOI] [PubMed] [Google Scholar]
  • 97.Zhang C., He X.J., Li L., Lu C., Lu A.P. Effect of the natural product triptolide on pancreatic cancer: a systematic review of preclinical studies. Front Pharmacol. 2017;8:490. doi: 10.3389/fphar.2017.00490. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Acta Pharmaceutica Sinica. B are provided here courtesy of Elsevier

RESOURCES